Publications by authors named "Manon Marcu"

Claim this Profile
F
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity.
Chrystelle Brignone, Maya Gutierrez, Fawzia Mefti, Etienne Brain, Rosana Jarcau, Manon Marcu

J Transl Med· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma.
Chrystelle Brignone, Bernard Escudier, Caroline Grygar, Manon Marcu, Frédéric Triebel

Clin Cancer Res· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells.
Chrystelle Brignone, Caroline Grygar, Manon Marcu, Knut Schäkel, Frédéric Triebel

J Immunol· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: a single-blind phase I study.
Chrystelle Brignone, Caroline Grygar, Manon Marcu, Gaëlle Perrin, Frédéric Triebel

Vaccine· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study.
Chrystelle Brignone, Caroline Grygar, Manon Marcu, Gaëlle Perrin, Frédéric Triebel

J Immune Based Ther Vaccines· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis